Comparing Mini Sarcopenia Risk Assessment With SARC-F for Screening Sarcopenia in Community-Dwelling Older Adults
Overview
Authors
Affiliations
Objective: The Mini Sarcopenia Risk Assessment (MSRA), a new sarcopenia screening tool, has 2 versions: MSRA-7 (full version, 7 items) and MSRA-5 (short version, 5 items). We aimed to compare the diagnostic values of MSRA-7 and MSRA-5 to SARC-F for screening sarcopenia.
Design: A diagnostic accuracy study.
Setting: A community in Chengdu, China.
Participants: Older adults.
Measurements: Muscle mass, strength, and physical performance were tested using a bioimpedance analysis (BIA) device, handgrip strength, and walking speed, respectively. Using the Asian Working Group for Sarcopenia (AWGS) criteria as the gold standard, the sensitivity/specificity analyses of the 3 scales were assessed. Receiver operating characteristic (ROC) curves and area under the ROC curves (AUC) were used to compare the overall diagnostic accuracy of the 3 scales.
Results: We recruited 384 participants. Against the AWGS criteria, SARC-F had a sensitivity of 29.5% and a specificity of 98.1%, and the MSRA-7 had a sensitivity of 86.9% and a specificity of 39.6%, whereas the MSRA-5 had a sensitivity of 90.2% and a specificity of 70.6%. The AUCs of SARC-F, MSRA-7, and MSRA-5 were 0.89 [95% confidence interval (CI), 0.86-0.92], 0.70 (95% CI, 0.65-0.74), and 0.85 (95% CI, 0.81-0.89), respectively. The differences in AUCs between SARC-F and MSRA-7 and in those between MSRA-7 and MSRA-5 were statistically significant (P <.001), but the difference between SARC-F and MSRA-5 was not statistically significant (P = .130).
Conclusion: MSRA-5 may serve as a novel screening tool for sarcopenia in Chinese community-dwelling older adults. SARC-F, a class screening tool, is also suitable for this population. MSRA-5 and SARC-F demonstrated a similar diagnostic accuracy in our study population. MSRA-5 has better sensitivity, whereas SARC-F has better specificity. However, the diagnostic value of MSRA needs to be further validated in different populations.
Vanitcharoenkul E, Unnanuntana A, Chotiyarnwong P, Adulkasem N, Asavamongkolkul A, Laohaprasitiporn P BMC Geriatr. 2024; 24(1):1043.
PMID: 39732657 PMC: 11681680. DOI: 10.1186/s12877-024-05637-3.
Moreno-Sanchez I, Aibar-Almazan A, Carcelen-Fraile M, Parra-Diaz A, Sanchez-Montesinos Garcia I, Sanchez-Alcala M Diagnostics (Basel). 2024; 14(19).
PMID: 39410528 PMC: 11475985. DOI: 10.3390/diagnostics14192123.
Rivera F, Adizas A, Cubarrubias D, Bantayan N, Choi S, Carado G J ASEAN Fed Endocr Soc. 2024; 39(1):84-94.
PMID: 38863907 PMC: 11163315. DOI: 10.15605/jafes.039.01.04.
Qian S, Zhang S, Lu M, Chen S, Liu L, Liu S Front Public Health. 2024; 12:1310383.
PMID: 38375338 PMC: 10876058. DOI: 10.3389/fpubh.2024.1310383.
Voulgaridou G, Tyrovolas S, Detopoulou P, Tsoumana D, Drakaki M, Apostolou T Nutrients. 2024; 16(3).
PMID: 38337720 PMC: 10856900. DOI: 10.3390/nu16030436.